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Prenatal exposure to TiO2 nanoparticles in
mice causes behavioral deﬁcits with
relevance to autism spectrum disorder and
beyond
Tina Notter1,2, Leonie Aengenheister3, Ulrike Weber-Stadlbauer1,2, Hanspeter Naegeli1, Peter Wick3, Urs Meyer 1,2 and
Tina Buerki-Thurnherr3
Abstract
Environmental factors are involved in the etiology of autism spectrum disorder (ASD) and may contribute to the raise
in its incidence rate. It is currently unknown whether the increasing use of nanoparticles such as titanium dioxide (TiO2
NPs) in consumer products and biomedical applications may play a role in these associations. While nano-sized TiO2 is
generally regarded as safe and non-toxic, excessive exposure to TiO2 NPs may be associated with negative health
consequences especially when occurring during sensitive developmental periods. To test if prenatal exposure to TiO2
NPs alters fetal development and behavioral functions relevant to ASD, C57Bl6/N dams were subjected to a single
intravenous injection of a low (100 µg) or high (1000 µg) dose of TiO2 NPs or vehicle solution on gestation day 9. ASD-
related behavioral functions were assessed in the offspring using paradigms that index murine versions of ASD
symptoms. Maternal exposure to TiO2 NPs led to subtle and dose-dependent impairments in neonatal vocal
communication and juvenile sociability, as well as a dose-dependent increase in prepulse inhibition of the acoustic
startle reﬂex of both sexes. These behavioral alterations emerged in the absence of pregnancy complications. Prenatal
exposure to TiO2 NPs did not cause overt fetal malformations or changes in pregnancy outcomes, nor did it affect
postnatal growth of the offspring. Taken together, our study provides a ﬁrst set of preliminary data suggesting that
prenatal exposure to nano-sized TiO2 can induce behavioral deﬁcits relevant to ASD and related neurodevelopmental
disorders without inducing major changes in physiological development. If extended further, our preclinical ﬁndings
may provide an incentive for epidemiological studies examining the role of prenatal TiO2 NPs exposure in the etiology
of ASD and other neurodevelopmental disorders.
Introduction
Autism spectrum disorder (ASD) is a group of neuro-
developmental disorders with increasing incidence rates.
According to the Center for Disease Control and Pre-
vention, the prevalence of ASD has doubled within the
last decade1, with current estimates suggesting that 1 in
68 American children is diagnosed with ASD1. Whilst
increased awareness, reclassiﬁcation, diagnostic expan-
sion, and inclusion of milder neurodevelopmental deﬁcits
likely contribute to the marked increase in the rate of
diagnosed ASD2, changes in the environment may add to
this increase as well3,4. The latter hypothesis is supported
by recent studies suggesting that 40–50% of variance in
ASD liability may be determined by environmental risk
factors5,6.
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In accordance with the developmental origin of ASD,
most of the identiﬁed environmental risk factors act
during pre- or perinatal periods. Examples of pre- or
perinatal risk factors include maternal exposure to
infection and/or inﬂammation7–10, maternal allergic-
asthma11,12, maternal autoantibodies reacting with fetal
proteins13,14, obstetric complications such as maternal
hypertension and preeclampsia15,16, and pre- and/or
perinatal exposure to (trafﬁc-related) air pollution17,18.
The latter is of particular interest as it may be related to,
or even driven by, the continuing urbanization, which in
itself is considered an environmental risk factor of ASD19.
In addition to air pollution, early-life exposure to various
other environmental toxicants, including mercury, lead,
arsenic, polychlorinated biphenyls and toluene, are known
causes of neurodevelopmental disorders and may play a
role in the etiology of ASD20.
The increasing use of nanoparticles (NPs) in various
consumer products and biomedical applications may
represent another challenge for public health21,22. NPs are
particles with at least one dimension below 100 nm and
can be engineered with distinctive compositions, sizes,
shapes, and surface chemistries23. Among the most fre-
quently produced and used NPs are those that are based
on titanium dioxide (TiO2)
24,25. Their unique physico-
chemical and optical properties enable the application of
TiO2 NPs as additives in various consumer products,
including toothpaste, sunscreen, paints, and food
(E171)24,26. In 2005 the worldwide production of titanium
powder was approximately 5 million tons27. According to
recent estimations, the proportion of nano-sized TiO2 in
titanium powder increased from 2.5% in 2009 to 10% in
201527,28.
Nano-sized particles such as TiO2 NPs can either
penetrate intact cell membranes29 or can be taken up via
endocytosis to cross biological barriers30,31. Hence, even if
the majority of TiO2 NPs may be excreted rapidly upon
uptake, a certain amount of nano-sized TiO2 particles can
be absorbed and disseminated into various tissues by the
systemic circulation26,32,33. While TiO2 NPs are generally
regarded as safe and non-toxic, a number of studies have
raised possible health concerns in relation to the
increasing use of nano-sized TiO2 particles
26,34,35. Expo-
sure to TiO2 NPs may be associated with negative health
consequences especially when occurring during develop-
mental periods. For example, studies in mice have found
that TiO2 NPs can cross the placental–fetal barrier and
induce moderate to severe malformations of the devel-
oping fetuses36,37. Prenatal exposure to TiO2 NPs in mice
was further shown to alter gene expression proﬁles in the
developing brain38 and to change cortical neuro-
transmitter levels in adolescent offspring39. Moreover,
recent studies suggest that prenatal TiO2 NP exposure
can induce long-term behavioral deﬁcits relevant to
depression40 and cognitive impairments in rats41,42.
In keeping with the increasing use of TiO2 NPs and the
rise in the incidence rates of ASD, we sought to evaluate
whether prenatal exposure to nano-sized TiO2 may alter
brain and behavioral development in a manner that is
relevant to ASD. To this end, we exposed pregnant mice
to distinct doses of TiO2 NPs or control treatment and
explored ASD-related behavioral functions in the result-
ing offspring. The behavioral tests included paradigms
assessing murine versions of core symptoms of ASD,
including impairments in social interaction, deﬁcits in
verbal communication, and presence of stereotyped/
repetitive behaviors43. We also included tests for anxiety-
like behavior and prepulse inhibition in attempts to
examine ASD-related symptoms of anxiety and altered
sensorimotor gating44,45. To assess the distribution of
TiO2 NPs following maternal exposure, we measured the
contents of titanium (Ti) in distinct maternal tissues
(liver, spleen, plasma), placenta, fetal liver, and fetal brain.
All investigations were conducted in male and female
offspring in order to reveal potential sex-dependent
effects.
Material and methods
Animals
C57Bl6/N mice were used throughout this study (Sup-
plementary Information). All procedures involving animal
experimentation had been previously approved by the
Cantonal Veterinarian’s Ofﬁce of Zurich, and all efforts
were made to minimize the number of animals used and
their suffering.
TiO2 NP suspension
TiO2 anatase NPs (NM-101) were provided by the Joint
Research Center (JRC, Ispra, Italy). The TiO2 NP powder
was dissolved in sterile and pyrogen-free phosphate-buf-
fered saline (PBS) (D8537, Sigma-Aldrich, Switzerland)
(5 mg/mL) via probe sonication (5 min at 13W, on ice;
Branson soniﬁer 250, Branson Ultrasonic Co., Danbury,
CT, USA). Detailed information about the characteriza-
tion of TiO2 NP suspension is provided in the Supple-
mentary Information.
Prenatal TiO2 NP exposure
C57BL6/N female mice were subjected to a timed
mating procedure as described previously46. Pregnant
dams were subjected to a single intravenous injection of
the 100 µg or 1000 µg TiO2 NP solution (see above) or
vehicle solution (PBS) on gestation day 9 (GD) 9 (Sup-
plementary Information). Two cohorts of pregnant mice
were generated under identical experimental and housing
conditions (see Supplementary Information). The ﬁrst
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cohort of dams was designated to fetal developmental and
Ti tissue distribution studies and the second cohort was
used to generate offspring for behavioral studies (see
Supplementary Information).
The methods used for maternal and fetal tissue collec-
tion for ICP-MS and evaluation of fetal development are
described in the Supplementary Information.
Behavioral testing in the offspring
Male and female offspring were behaviorally tested in
paradigms that indexed murine versions of ASD symp-
toms, including deﬁcits in verbal communication,
impairments in social interaction, and presence of ste-
reotyped/repetitive behaviors43. Behavioral assessing also
included tests for anxiety-like behavior and prepulse
inhibition in attempts to examine ASD-related symptoms
of anxiety and altered sensorimotor gating44,45. While
verbal communication was assessed in neonatal mice on
postnatal day (PND) 6, all other tests were conducted in a
separate subgroup of offspring when they reached the
juvenile stage (i.e., between PND 28 and 42). Juvenile
offspring were repeatedly tested in the following order,
with a testing-free resting period of 2 days between
individual tests: (1) open ﬁeld test, (2) social interaction
test, (3) self-grooming test, and (4) prepulse inhibition
(PPI) test. A detailed description of the test apparatuses
and procedures is provided in the Supplementary
Information.
Statistical analyses
All data met the assumptions of normal distribution and
equality of variance. All data were analyzed using para-
metric analysis of variance (ANOVA) as described in the
Supplementary Information. Whenever appropriate, all
ANOVAs were followed by Fisher’s least signiﬁcant dif-
ference (LSD) post-hoc tests. All statistical analyses were
performed using StatView (version 5.0; Abacus, Phoenix,
AZ, USA) implemented on a PC running the Windows
XP operating system, and Prism software (version 7.0;
GraphPad Software, La Jolla, CA, USA). Statistical sig-
niﬁcance was set at p < 0.05 for all tests. No exclusion
criteria were applied.
Results
Tissue distribution of TiO2 NPs
Well-characterized anatase TiO2 NPs from the JRC
repository (NM-101) were used for this study (see Sup-
plementary Table 2). Ultrasensitive sector ﬁeld-
inductively coupled plasma mass spectrometry revealed
that maternal TiO2 NP treatment led to a dose- and
tissue-dependent accumulation of Ti, as supported by the
signiﬁcant main effect of prenatal treatment (F(2, 72)=
110.5, p < 0.001), tissue compartment (F(5, 72)= 62.36, p <
0.001), and their interaction (F(10,72)= 44.6, p < 0.001). As
illustrated in Supplementary Fig. 1, Ti was found to
accumulate in maternal liver and spleen. Post-hoc com-
parisons of maternal liver and spleen samples conﬁrmed a
dose-dependent increase in Ti between control animals
(0 µg) and animals exposed to 100 µg (liver: p < 0.001,
spleen: p < 0.001) or 1000 µg (liver: p < 0.001, spleen: p <
0.001), and between animals exposed to 100 µg and
1000 µg (liver: p < 0.001, spleen: p < 0.001). On the other
hand, there was no signiﬁcant accumulation of Ti in
maternal plasma, placenta, fetal liver, and fetal brain
(Supplementary Fig. 1).
Effects of maternal TiO2 NP exposure on pregnancy
outcomes and offspring development
Maternal exposure to TiO2 NPs did not affect fetal
length (F(2,21)= 0.129, p= 0.879), fetal weights (F(2,21)=
0.845, p= 0.444), and fetal brain weights (F(2,21)= 0.036,
p= 0.964) (Supplementary Fig. 2b). Likewise, a gross
examination of the fetal morphology did not reveal
noticeable differences between fetuses of control dams
and dams exposed to TiO2 NPs (Supplementary Fig. 2a).
Hence, maternal exposure to TiO2 NPs did not cause
overt signs of fetal malformations.
In agreement with these ﬁndings, maternal exposure to
TiO2 NPs did not affect litter sizes (F(2,22)= 0.270, p=
0.766; Supplementary Fig. 2c) or the male/female ratio of
the delivered pups (F(2,22)= 1.63, p= 0.23; Supplementary
Fig. 2d). The offspring’s body weights were also not
changed by the prenatal manipulation. As expected, the
offspring’s body weights increased from neonatal (PND 6)
to juvenile (PND 21 and 28) ages (main effect of age:
F(2,149)= 2430.884, p < 0.001; Supplementary Fig 2e), and
this age effect was not inﬂuenced by prenatal treatment
(main effect of prenatal treatment: F(2,149)= 0.046, p=
0.955; interaction between prenatal treatment and age:
F(4,149)= 0.394, p= 0.813). Female offspring generally
weighed less than male offspring (main effect of sex:
F(1,149)= 65.507, p < 0.001), regardless of their prenatal
treatment conditions (interaction between prenatal
treatment and sex: F(2,149)= 1.093, p= 0.338). Together,
these ﬁndings indicate that maternal exposure to TiO2
NPs did not affect pregnancy outcomes or postnatal
development of the offspring.
Effects of maternal TiO2 NP exposure on neonatal
ultrasonic vocalization
Verbal communication was assessed in neonatal mice
by measuring USV calls upon acute separation from their
littermates and rearing mothers. Prenatal TiO2 NP
exposure led to a dose-dependent decrease in the total
numbers of USV calls emitted from pups that were
separated from their mothers (main effect of prenatal
treatment: F(2,43)= 5.361, p < 0.01) (Fig. 1b). Post-hoc
analyses conﬁrmed signiﬁcantly decreased USV calls in
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neonates of mothers that were treated with 1000 µg TiO2
NPs relative to control neonates (p < 0.01) or to neonates
of mothers that were treated with 100 µg TiO2 NPs (p <
0.05) (Fig. 1b). These effects were sex-independent (main
effect of sex: F(1,43)= 1.703, p= 0.199; interaction
between prenatal treatment and sex: F(2,43)= 0.028,
p= 0.973). In contrast to its effects on the number of
USVs, prenatal TiO2 NP exposure did not affect the mean
duration of USV calls (main effect of prenatal treatment:
F(2,43)= 1.187, p= 1.187; interaction between prenatal
treatment and sex: F(2,43)= 0.035, p= 0.966) (Fig. 1c).
There were also no group differences in terms of the
mean dominant frequency of emitted USV calls (main
effect of prenatal treatment: F(2,43)= 2.534, p= 0.091;
interaction between prenatal treatment and sex: F(2,43)=
1.437, p= 0.249) (Fig. 1d).
Effects of maternal TiO2 NP exposure on sociability and
repetitive behavior
Sociability of juvenile offspring was assessed using a
modiﬁed version of the three-chamber social interaction
test46,47. In this test, sociability was indexed as the relative
exploration time between an unfamiliar, congenic mouse
of the same sex and an inanimate dummy object. Prenatal
TiO2 NP exposure caused a dose-dependent deﬁcit in
social approach behavior (Fig. 2a), as supported by the
main effect of prenatal treatment (F(2,53)= 4.838, p < 0.05)
and by the subsequent post-hoc analyses revealing a sig-
niﬁcant difference between offspring of mothers that were
treated with 1000 µg TiO2 NPs and control offspring (p <
0.05) or offspring of mothers that were treated with
100 µg TiO2 NPs (p < 0.05). The effect of prenatal TiO2
NP exposure on sociability emerged independently of sex
(main effect of sex: F(1,53)= 0.959, p= 0.332; interaction
between prenatal treatment and sex: F(2,53)= 0.091, p=
0.914) and was not associated with concomitant changes
in locomotor activity (Fig. 2a). The latter was indexed by
the total distance moved during the social interaction test,
which did not yield any signiﬁcant effects (main effect of
prenatal treatment: F(2,53)= 0.771, p= 0.468; main effect
of sex: F(1,53)= 2.740, p= 0.104; interaction between
prenatal treatment and sex: F(2,53)= 0.247, p= 0.782).
A self-grooming test was used to explore repetitive
behavior in juvenile offspring. As illustrated in Fig. 2b,
Fig. 1 Ultrasonic vocalizations (USV) measured in neonatal offspring prenatally exposed to 0 (=vehicle), 100, or 1000 µg TiO2. a
Representative spectrograms of USVs emitted from separated pups. b The bar plot represents the number of emitted USV calls. *p < 0.05 and ***p <
0.001. c The bar plot depicts the mean duration (ms) of emitted USV calls. d The bar plot depicts the mean dominant frequency of emitted USV calls
in kHz. All data are based on N(0 µg)= 16 (8m, 8f), N(100 µg)= 16 (8m, 8f) and N(1000 µg)= 17 (9m, 8f). All values are means ± SEM
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offspring of mothers that were treated with TiO2 NPs
showed a trend towards increased levels of self-grooming
relative to control offspring (main effect of prenatal
treatment: F(2,53)= 2.668, p= 0.079). The main effect of
sex (F(1,53)= 0.924, p= 0.341) and its interaction with
prenatal treatment (F(2,53)= 0.772, p= 0.462) were far
from being signiﬁcant.
Effects of maternal TiO2 NP exposure on sensorimotor
gating
Sensorimotor gating was assessed in juvenile offspring
using PPI of the acoustic startle reﬂex. Prenatal TiO2 NP
exposure signiﬁcantly altered % PPI, as indicated by the
main effect of prenatal treatment (F(2,53)= 4.469, p <
0.05). Post-hoc analyses revealed that offspring prenatally
exposed to 1000 µg TiO2 NPs displayed signiﬁcantly
increased % PPI relative to offspring exposed to 100 µg
TiO2 NPs (p < 0.01) and control offspring (p < 0.05) (Fig.
3a). The effect of prenatal TiO2 NP exposure on % PPI
was independent of sex (main effect of sex: F(1,53)= 1.710,
p= 0.197; interaction with prenatal treatment and sex:
F(2,53)= 0.260, p= 0.772). The increase in % PPI displayed
in offspring of mothers that were exposed to 1000 µg TiO2
NPs appeared to be largest in conditions, in which
100 dBA stimuli served as pulse stimuli (Fig. 3a); however,
the interaction between prenatal treatment and pulse
stimulus was not signiﬁcant (F(4,106)= 2.187, p= 0.085).
The interaction between prenatal treatment and prepulse
was far from being signiﬁcant (F(4,106)= 0.209, p= 0.933),
indicating that the effect of prenatal TiO2 NP exposure on
% PPI emerged independently of prepulse intensity.
Prenatal TiO2 NP exposure did not affect the reactivity
to pulse-alone trials (F(2,53)= 0.161, p= 0.852); (Fig. 3b)
or prepulse-alone trials (F(2,53)= 0.477, p= 0.623); (Fig.
3c). As expected47, the reactivity to pulse-alone and
prepulse-alone trials increased with increasing pulse and
prepulse intensities, respectively (main effect of pulse:
F(2,106)= 378.790, p < 0.001; main effect of prepulse:
F(2,106)= 17.886, p < 0.001).
Effects of maternal TiO2 NP exposure on anxiety-like
behavior
Innate anxiety-like behavior was assessed in juvenile
offspring using the open-ﬁeld exploration task. As illu-
strated in Fig. 4a, prenatal TiO2 NP exposure did not
affect the time spent in the center zone of the open ﬁeld
during 10min of free exploration (main effect of prenatal
treatment: F(2,53)= 0.773, p= 0.467; main effect of sex:
F(1,53)= 1.167, p= 0.285; interaction between prenatal
treatment and sex: F(2,53)= 0.349, p= 0.707). Likewise,
the prenatal manipulation did not inﬂuence general
locomotor activity indexed by the total distance moved
(main effect of prenatal treatment: F(2,53)= 2.800, p=
0.070) (Fig. 4b). As expected48, the total distance moved
was generally higher in female as compared to male off-
spring (main effect of sex: F(1,53)= 13.76, p < 0.001), and
this effect similarly emerged in all prenatal treatment
groups (interaction between prenatal treatment and sex:
F(2,53)= 1.976, p= 0.149).
Discussion
The present study demonstrates that maternal exposure
to nano-sized TiO2 leads to a dose-dependent disruption
of behavioral functions in mice. The spectrum of beha-
vioral deﬁcits induced by prenatal TiO2 NP exposure
included impairments in neonatal vocal communication
and juvenile social interaction, as well as increased PPI of
the acoustic startle reﬂex in juvenile offspring. The neo-
natal deﬁcits in vocal communication were manifest as a
reduction in USV rates when pups were separated from
Fig. 2 Social interaction and stereotyped/repetitive behavior in juvenile offspring prenatally exposed to 0 (=vehicle), 100, or 1000 µg
TiO2. a The bar plots depict the percent time spent with an unfamiliar mouse and the total distance moved during the social interaction test. *p <
0.05. b The bar plot depicts the time spent self-grooming during a period of 10 min. All data are based on N(0 µg)= 20 (10m, 10f), N(100 µg)= 19
(10m, 9f), N(1000 µg)= 20 (10m, 10f). All values are means ± SEM
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their littermates and rearing mother and thus likely reﬂect
altered affective states promoting separation-induced
vocal responses. The dose-dependent deﬁcit in social
approach behavior induced by prenatal TiO2 NP exposure
was not associated with concomitant alterations in innate
anxiety-like behavior, and therefore, it likely represents a
genuine impairment in sociability towards unfamiliar
conspeciﬁcs. Finally, the observed increase in PPI of the
acoustic startle reﬂex may reﬂect hypersensitivity to sen-
sory information. The consensus is that PPI reﬂects the
ability to ﬁlter out irrelevant information in the early
stages of processing so that attention can be directed to
more salient environmental features49. Generally, stronger
and/or more salient prepulses induce higher levels of PPI
as they are more efﬁcient in inhibiting the processing of
the subsequent pulse stimulus. On speculative grounds,
prepulses may be more salient for offspring that were
prenatally exposed to the highest dose of TiO2 as com-
pared to control offspring, and consequently, they would
be more efﬁcacious in inhibiting the subsequent pulse-
stimulus processing in TiO2-exposed offspring, thereby
leading to increased PPI.
Interestingly, the TiO2-induced disruption of behavioral
functions was independent of the offspring’s sex, indi-
cating similar vulnerabilities of the male and female sex to
this environmental hazard. Prenatal exposure to nano-
sized TiO2 did also not cause overt fetal malformations or
changes in pregnancy outcomes, nor did it affect postnatal
growth of the offspring. Taken together, our mouse model
suggests that prenatal TiO2 exposure can induce
Fig. 3 Prepulse inhibition of the acoustic startle reﬂex in juvenile offspring prenatally exposed to 0 (=vehicle), 100, or 1000 µg TiO2. a The
line plot depicts percent prepulse inhibition as a function of different pulse intensities (P-100, P-110 and P-120, corresponding to 110, 110, and
120 dBA) and prepulse intensities (+6, +12, and +18 dBA above background of 65 dBA). The bar plot shows the mean prepulse inhibition scores
across all pulse and prepulse conditions. *p < 0.05. b The line plot depicts the startle response to pulse-alone stimuli as a function of pulse intensities
(110, 110, and 120 dBA). c The line plot depicts the reactivity to prepulse-alone stimuli as a function of prepulse intensities (71, 77, and 83 dBA). All data
are based on N(0 µg)= 20 (10m, 10f), N(100 µg)= 19 (10m, 9f), N(1000 µg)= 20 (10m, 10f). All values are means ± SEM
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behavioral abnormalities in both sexes without inducing
major changes in physiological development.
Relevance to autism spectrum disorder and beyond
A number of behavioral alterations emerging in off-
spring that were prenatally exposed to the highest dose of
nano-sized TiO2, including impairments in vocal com-
munication and social interaction, resemble core features
of ASD50. These core deﬁcits often emerge as early as in
the ﬁrst years of life and tend to persist throughout life in
ASD subjects51,52. It should be noted, however, that our
study does not offer a direct link between these two
behavioral impairments, given that vocal communication
was measured in neonatal offspring, whereas social
interaction was assessed at the juvenile stage of life. In
addition to vocal and social deﬁcits, the TiO2-induced
changes in PPI may also have some relevance for ASD.
While PPI was found to be decreased in a subset of adults
with ASD53,54, increased PPI of the acoustic startle reﬂex
has been reported for children with ASD55. Our ﬁndings
recapitulate the latter, given that our study examined PPI
in juvenile offspring of TiO2-exposed mothers and con-
trols. Increased PPI in children with ASD has been related
to hypersensitivity to sensory information, which may
stem from changes in the perceived salience of seemingly
irrelevant stimuli such as prepulses of low intensity.
Despite the fact that prenatal TiO2 exposure resulted in
ASD-related behavioral deﬁcits, it should be noted that
these deﬁcits were relatively subtle and did not extend to
other core behavioral abnormalities that are frequently
observed in ASD, including repetitive and anxiety-like
behaviors43. Furthermore, our ﬁndings do by no means
imply that prenatal TiO2 exposure may cause behavioral
abnormalities that are speciﬁc to ASD. In fact, this
environmental hazard may also contribute to other brain
disorders, including depression-like behavior and cogni-
tive deﬁcits. For example, a previous study in rats showed
that prenatal exposure to TiO2 caused anhedonic beha-
vior and behavioral despair, as assessed using the sucrose
preference test and forced swimming test, respectively40.
Furthermore, maternal administration of TiO2 in rats was
found to impair various cognitive functions, including
spatial and non-spatial learning and memory41,42. Since
our study did not assess functions in these behavioral and
cognitive domains, we cannot directly compare our data
to these previous ﬁndings. Taken together, however, the
available data suggest that prenatal exposure to TiO2 may
be a general vulnerability factor for various brain dis-
orders with neurodevelopmental etiologies.
Tissue distribution of TiO2 NPs and possible mediating
mechanisms
In line with previous systemic exposure studies in
rodents33,56,57, we found that Ti accumulated primarily in
the maternal liver and spleen after i.v. administration of
TiO2 NPs. By contrast, we did not detect increased Ti
levels in the placenta or in fetal brain and liver tissues,
suggesting that the majority of the maternally adminis-
tered TiO2 particles did not accumulate in or cross the
maternal-fetal interface. Therefore, it seems unlikely that
a direct fetal exposure to TiO2 NPs is responsible for the
subsequent emergence of behavioral abnormalities.
Rather, the effects of prenatal TiO2 exposure may be
driven by pathophysiological processes that arise in the
maternal system and induce secondary effects in the
offspring.
At present, the nature of these pathophysiological
processes remains elusive and warrants identiﬁcation
in future studies. One candidate mechanism may
involve alterations in the maternal immune system. In
support of this hypothesis, it was previously shown that
exposure to TiO2 NPs can induce signs of inﬂamma-
tion and other immune abnormalities, both in vivo and
in vitro58–60. Given that abnormal immune functions
and maternal inﬂammation have themselves been
implicated in the etiology of ASD7–14, a link between
prenatal exposure to TiO2, immune abnormalities, and
emergence of ASD-related deﬁcits seems biologically
plausible. This hypothesis also warrants further
exploration in view of the parallels between our ﬁnd-
ings and those reported in animal models of prenatal
inﬂammation and other immune abnormalities.
Indeed, prenatal exposure to immune challenges such
as viral- or bacterial-like acute phase responses7,61–63
or allergy-like immune imbalances11,64 have been
shown to induce similar ASD-related behavioral
abnormalities as those reported here.
Fig. 4 Innate anxiety-like behavior measured in juvenile offspring
prenatally exposed to 0 (=vehicle), 100, or 1000 µg TiO2. Innate
anxiety-like behavior was assessed using a 10 min open ﬁeld test. a
The bar plot represents the time spent in the center zone of the open
ﬁeld arena. b The bar plot depicts the total distance moved in the
entire arena. All data are based on N(0 µg)= 20 (10m, 10f), N(100 µg)
= 19 (10m, 9f), and N(1000 µg)= 20 (10m, 10f). All values are means ±
SEM
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An alternative (but mutually not exclusive) possibility is
that maternal TiO2 exposure could cause abnormal
development and functions of the placenta even in the
absence of placental accumulation of TiO2 NPs. The role
of placental abnormalities in the etiology of ASD has
received increasing recognition in recent years15,65. Being
the critical sustenance delivery system for the fetus, pla-
cental health is critical for fetal growth and develop-
ment66. Importantly, acting as the interface to
communicate maternal nutritional and environmental
statuses, the placenta rapidly responds to alterations in
the maternal milieu and integrates the pathophysiological
effects induced by a number of environmental adver-
sities66. While various NPs have been associated with
reproductive toxicity67, recent evidence suggests that this
may also be the case for TiO2 NPs. For example, it was
recently shown in mice that maternal exposure to TiO2
starting from conception to late gestation affected pla-
cental micronutrients and reduced placental weights68.
Hence, the disruption of placental development and
function may represent another possible mechanism by
which maternal exposure to nano-sized TiO2 can induce
ASD-relevant behavioral abnormalities in the offspring.
A third possible mechanism underlying the disruption
of behavioral development following prenatal TiO2
exposure may involve changes in the maternal micro-
biota69. This hypothesis warrants exploration in view of
the accumulating evidence suggesting that dysbiosis of the
maternal microbiome can induce altered brain and
behavioral development in the offspring with relevance to
ASD and beyond70. In fact, alterations in the maternal
microbiome may represent a common pathophysiological
mechanism mediating the negative effects of a number of
prenatal adversities, including maternal exposure to
stress71, immune activation72, and high-fat diets73.
Extrapolation to human exposures
The continuous rise in TiO2-containing products
increases the human exposure to nano-sized TiO2. For
example, the dietary intake of TiO2 in the US is estimated
to be 1–2mg/kg body weight per day for children, and
0.2–0.7 mg/kg body weight per day for other age
groups24,26. Food-grade TiO2 particles are frequently used
as white colorant and typically have a mean size of
>100 nm, thus exceeding nano-size scales24. Nevertheless,
approximately up to one third of TiO2 particles in com-
mon food products are nano-sized (<100 nm)24,26, sug-
gesting that the daily ingestion of TiO2 NPs via common
food products is considerable. According to recent bioa-
vailability studies in humans, however, only a small pro-
portion (~0.1%) of the ingested TiO2 NPs reaches the
systemic circulation74. The low bioavailability of orally
administered TiO2 NPs contrast the bioavailability of
TiO2 NPs in our study, which was 100% as a result of the
i.v. administration regimen. Given these differences in
bioavailability, one could argue that our ﬁndings are
artiﬁcial, and therefore, irrelevant for human conditions,
where most of the TiO2 NPs reach the body via the oral
route or inhalation26,34,35,75. While we appreciate the
limitations of the chosen experimental design, we deem
our study relevant for various reasons. First, given that
TiO2 NPs can persist in tissues such as liver and spleen
once absorbed33, it is likely that even limited systemic
absorption can result in tissue accumulation, especially
upon chronic exposure26,33. Secondly, our study empha-
sizes that a single exposure to high doses of TiO2 NPs in
prenatal life is sufﬁcient to induce long-term behavioral
changes. Nano-sized TiO2 has been in discussion for the
future use in biomedical applications, whereby the parti-
cles would serve as drug carriers and administered via the
i.v. route35,76. Thus, together with other preclinical studies
that were based on prenatal i.v. exposure to TiO2
NPs33,37,56,57,77, our ﬁndings emphasize the need of a
careful assessment of the possible beneﬁts and risks of
administering nano-sized TiO2 to pregnant women.
Limitations
Our study has a number of limitations. First, it did not
aim at identifying the post-acute mechanisms mediating
the effects of maternal TiO2 exposure on behavioral
development in the offspring. Second, the characteriza-
tion of the negative effects of prenatal TiO2 exposure was
conducted exclusively at the behavioral level and did not
encompass investigations of brain specimen. Hence, our
study did not provide a link between TiO2-induced
behavioral alterations and dysfunctions in speciﬁc neu-
ronal and/or glial systems. Finally, even if we included a
number of behavioral tests, the behavioral characteriza-
tion of the effects of prenatal TiO2 exposure was far from
exhaustive and did, for example, not involve the assess-
ment of cognitive functions. With respect to the latter,
future studies should also investigate whether this envir-
onmental hazard affects cognitive ﬂexibility and working
memory, both of which are altered in a subset of cases
with ASD and related neurodevelopmental disorders78,79.
Conclusion
Our study provides a ﬁrst set of preliminary data sug-
gesting that prenatal exposure to nano-sized TiO2 can
induce behavioral deﬁcits relevant to ASD and related
neurodevelopmental disorders. Human epidemiological
studies exploring associations between TiO2 exposure and
health outcomes are still rare and largely conﬁned to the
research of cancer and pulmonary diseases80–82. Hence,
our ﬁndings cannot be compared directly to human epi-
demiological data collected in the context of ASD, nor
should they be taken to predict ASD risk in human
populations. At the same time, however, our ﬁndings may
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provide an incentive for epidemiologists and basic scien-
tists alike to further examine the role of prenatal TiO2
exposure in the etiology of ASD and other neurodeve-
lopmental disorders. Such studies may also help to
ascertain whether the increasing use of NPs such as nano-
sized TiO2 contributes in some way to the rise in the
incidence rates of these disorders.
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